Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
October 12, 2021 16:05 ET
|
Homology Medicines, Inc.
- IND Clearance of pheEDIT Study to Evaluate a One-Time Dose of Investigational HMI-103 Incorporating a Novel Nuclease-Free Gene Editing Approach - - Company Provides Update on Enrollment in...
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
August 12, 2021 16:05 ET
|
Homology Medicines, Inc.
- On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021- - Plans to Initiate First-Ever Gene Editing Trial for PKU with HMI-103 This Year - - Expects...
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board
August 05, 2021 08:30 ET
|
Homology Medicines, Inc.
- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines,...
Homology Medicines to Participate in Upcoming Investor Conferences
August 04, 2021 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the...
Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting
May 13, 2021 07:00 ET
|
Homology Medicines, Inc.
- Data From New GTx-mAb Platform Demonstrated Proof of Principle for AAVHSCs to Deliver One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model - - Additional Data for HMI-203...
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
May 06, 2021 16:05 ET
|
Homology Medicines, Inc.
- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End - - Announced New GTx-mAb Platform With Proof of Concept Data to Be Presented at Upcoming ASGCT Annual Meeting...
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting
May 03, 2021 08:00 ET
|
Homology Medicines, Inc.
- Data Showed AAVHSCs Edited Human Retinal Cell Types Across Two Targets - - Demonstrated 11 AAVHSC Capsids Crossed Blood-Retinal and Blood-Brain Barriers in In Vivo Studies of Non-Human Primates...
Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model
April 28, 2021 08:00 ET
|
Homology Medicines, Inc.
- Proof of Concept Data for New GTx-mAb Platform to Be Featured at ASGCT Along With Presentations From Multiple Programs - - Company to Host Webcast on May 13 at 8:15 a.m. ET - BEDFORD, Mass., April...
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
April 14, 2021 08:30 ET
|
Homology Medicines, Inc.
- Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations - BEDFORD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a...
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
April 12, 2021 08:30 ET
|
Homology Medicines, Inc.
- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership - BEDFORD, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Homology...